Mirikizumab Shows Success in Treating Pediatric Colitis
A new Phase 3 study indicates that mirikizumab helps children with active ulcerative colitis achieve significant remission.
Updated on Oct. 20, 2026 in Children’s Health
Live Poll
Do you trust that new medications approved for adults are sufficiently tested for pediatric use?
The Phase 3 SHINE-2 study found that mirikizumab is effective in treating pediatric patients with moderately to severely active ulcerative colitis. Half of the children in the study achieved clinical remission by the end of one year.
Why it matters
Researchers launched the study to address the significant shortage of advanced therapeutic options currently available for children suffering from this chronic inflammatory bowel condition.
In a study of 63 children, mirikizumab produced a 41.3% clinical remission rate at 12 weeks and a 50% rate at 52 weeks. Patients also saw fecal calprotectin levels drop by an average of 1,229.9 µg/g from baseline measurements by week 12.
The players
SHINE-2 study
This is a clinical research initiative designed to evaluate the safety and efficacy of mirikizumab in pediatric ulcerative colitis patients.
The details
Participants were administered intravenous induction doses followed by subcutaneous maintenance doses every four weeks to manage their condition. Two serious adverse events were documented, specifically a large intestinal polyp and a flare-up of the disease.
Timeline
Week 4: 38.1% of patients achieved symptomatic remission.
Week 12: Clinical remission reached 41.3%.
Week 52: The study met its primary endpoint of 50% clinical remission.
The Big Picture
This study marks a significant progression in the clinical application of mirikizumab by establishing its utility in younger demographics. It updates figures previously established by the SHINE-2 study protocols to include pediatric-specific outcomes.
This development may eventually provide pediatric patients with a new, targeted maintenance option for managing ulcerative colitis through periodic subcutaneous doses. Families should consult with their gastroenterologists to discuss how these findings relate to current treatment standards and potential future care pathways.
The takeaway
This study suggests that biologic therapy can be a viable path to remission for children who previously faced few advanced treatment alternatives. Clinicians and families may find these results encouraging as they evaluate long-term strategies for managing inflammatory bowel disease in youth.
Further reading
For more information on pediatric gastrointestinal care, visit the Children’s Health section.
Live Poll
Do you trust that new medications approved for adults are sufficiently tested for pediatric use?
